中国在线观看免费国语版,免费60分钟床片免费看,欧美日韩精品视频一区二区,欧美日韩中文字幕日韩欧美一区二区三区久久国产欧美日韩精品国产在线欧美日韩精品一区亚洲欧美中文日韩v在线观看亚洲中文欧美日韩在线不卡欧美日韩亚洲国内综合网国产精品国产精品一区精品国产自在现偷99精品国产在热2019国产拍偷精品网国产精品视频全国免费观看，国产精品v欧美精品v日韩精品青青精品视频国产久久国产精品久久精品国产亚洲精品国产精品国产欧美精品一区二区三区，国产精品第一页国产亚洲 欧美日韩中文字幕日韩欧美一区二区三区久久国产欧美日韩精品国产在线欧美日韩精品一区亚洲欧美中文日韩v在线观看亚洲中文欧美日韩在线不卡欧美日韩亚洲国内综合网国产精品国产精品一区精品国产自在现偷99精品国产在热2019国产拍偷精品网国产精品视频全国免费观看，国产精品v欧美精品v日韩精品青青精品视频国产久久国产精品久久精品国产亚洲精品国产精品国产欧美精品一区二区三区，国产精品第一页国产亚洲互動交流

Date: 23-March-2019  
Source:  Guangdong Tencent News

TAEST16001 of Xiangxue has been the first TCR-T IND (Investigational New Drug) in China approved by NMPA (National Medical Products Administration).

With independent intellectual property rights, Xiangxue Life Sciences has established a platform to develop cell-based therapies that take advantage of the unique attributes of TCR mediated target recognition. As first product of company, TAEST16001 reaches the international advanced level. Being considered of the highly effective technology for tumor vaccination, TCR-T has shown the potential to improve cure rate and to save lives of patients with malignant tumor.

廣州市香雪制藥股份有限公司子公司廣東香雪精準醫(yī)療技術有限公司向國家藥品監(jiān)督管理局提交的TAEST16001注射液新藥臨床注冊申請已獲得國內首個TCR-T臨床試驗許可。

香雪精準已建立TCR-T完整的技術平臺及工藝，具有完整的自主知識產權，TAEST16001注射液是香雪精準研發(fā)管線的第一個產品，達到了國際先進水平。特異性T細胞受體免疫治療技術（TCR-T）是目前在腫瘤免疫治療領域具有顯著療效的先進技術，可實現(xiàn)疾病的個體化精準治療，大大提高腫瘤的治愈率，從而有望從根本上治愈惡性腫瘤這一頑疾。